9M 2023 Financial Performance

9M 2023: Business update Brintellix/Trintellix growth trajectory in Europe continues Global Brintellix/Trintellix revenue (DKKm) 7 +4% CER DKK 3,207m DKK 3,177m -8% CER +16% CER +6% CER 9M 2022 United States Europe 9M 2023 International Markets Trintellix was approved by FDA September 2013 and Brintellix by EMA December 2013. 1) Reported revenue growth. 2) IQVIA data, value market share, September 2023. MDD: major depressive disorder Brintellix vortioxetine Trintellix vortioxetine • European market maintains strong momentum Solid performance in International Markets Growth driven by strong performance particularly in Canada and Japan First-line treatment positioning in Japan drives sales up +28%1) achieving a market share of 14.8%²) Changed MDD market dynamics in the U.S. • Shifting market dynamics in U.S. favoring adjunctive therapy in second line treatment • Volume seemed to stabilize over the last two quarters

View entire presentation